Brainstorm Cell Therapeutics (NASDAQ:BCLI) Cut to Sell at StockNews.com

StockNews.com lowered shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

Brainstorm Cell Therapeutics Trading Down 6.3 %

Shares of NASDAQ BCLI opened at $2.09 on Wednesday. The stock has a fifty day moving average price of $1.74 and a 200 day moving average price of $3.32. Brainstorm Cell Therapeutics has a 12-month low of $1.05 and a 12-month high of $11.89. The company has a market cap of $11.92 million, a P/E ratio of -0.44 and a beta of 0.29.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.